ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    lemborexant 108
Previous Study | Return to List | Next Study

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03008447
Recruitment Status : Recruiting
First Posted : January 2, 2017
Last Update Posted : November 21, 2017
Sponsor:
Collaborator:
Purdue Pharma LP
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
E2006-A001-108 is a 4-period crossover study designed to demonstrate that the mean change from baseline in postural stability (worsening) when participants are awakened at approximately 4 hours postdose is significantly less after lemborexant than after zolpidem tartrate extended release following a single-dose administration at bedtime.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: LEM5 Drug: LEM10 Drug: ZOL Drug: PBO Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: A Randomized, Double-Blind, Placebo-Controlled and Active Comparator, 4 Period Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older
Actual Study Start Date : November 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : January 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LEM5; LEM10; PBO; ZOL
Participants will receive LEM5 (one lemborexant [LEM] 5 milligram [mg] tablet and one zolpidem [ZOL]-matched placebo [PBO] tablet) in Treatment Period 1. In Treatment Period 2, participants will receive LEM10 (one LEM 10 mg tablet and one ZOL-matched PBO tablet). In Treatment Period 3, participants will receive PBO (one LEM-matched PBO tablet and one ZOL-matched PBO tablet). In Treatment Period 4, participants will receive ZOL (one LEM-matched PBO tablet and one ZOL 6.25 mg tablet).
Drug: LEM5
Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.

Drug: LEM10
Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.

Drug: ZOL
Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.

Drug: PBO
Single dose of placebo administered within 5 minutes before bedtime.

Experimental: LEM10; ZOL; LEM5; PBO
Participants will receive LEM10, ZOL, LEM5, and PBO in Treatments Periods 1, 2, 3, and 4, respectively.
Drug: LEM5
Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.

Drug: LEM10
Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.

Drug: ZOL
Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.

Drug: PBO
Single dose of placebo administered within 5 minutes before bedtime.

Experimental: ZOL; PBO; LEM10; LEM5
Participants will receive ZOL, PBO, LEM10, and LEM5 in Treatment Periods 1, 2, 3, and 4, respectively.
Drug: LEM5
Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.

Drug: LEM10
Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.

Drug: ZOL
Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.

Drug: PBO
Single dose of placebo administered within 5 minutes before bedtime.

Experimental: PBO; LEM5; ZOL; LEM10
Participants will receive PBO, LEM5, ZOL, and LEM10 in Treatment Periods 1, 2, 3, and 4, respectively.
Drug: LEM5
Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.

Drug: LEM10
Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.

Drug: ZOL
Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.

Drug: PBO
Single dose of placebo administered within 5 minutes before bedtime.




Primary Outcome Measures :
  1. Change from time-matched baseline in postural stability for LEM5 and LEM10 compared to zolpidem (ZOL) at approximately 4 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
    Magnitude of body sway upon being awakened at approximately 4 hours after receiving lemborexant 5 milligrams (mg) (LEM5), lemborexant 10 mg (LEM10), zolpidem 6.25 mg, or placebo.


Secondary Outcome Measures :
  1. Change from time-matched baseline in postural stability for LEM5 and LEM10 compared to ZOL and placebo (PBO) at approximately 8 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  2. Change from time-matched baseline in postural stability for LEM5 and LEM10 compared to PBO at approximately 4 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  3. Change from time-matched baseline in auditory awakening threshold (AAT) for LEM5 and LEM10 compared to ZOL and PBO at approximately 4 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  4. Change from time-matched baseline on summary variables from power of attention for LEM5 and LEM10 compared to ZOL and PBO at approximately 4 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  5. Change from time-matched baseline on summary variables from power of attention for LEM5 and LEM10 compared to ZOL and PBO at approximately 8 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  6. Change from time-matched baseline on summary variables from continuity of attention for LEM5 and LEM10 compared to ZOL and PBO at approximately 4 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  7. Change from time-matched baseline on summary variables from continuity of attention for LEM5 and LEM10 compared to ZOL and PBO at approximately 8 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  8. Change from time-matched baseline on summary variables from quality of memory for LEM5 and LEM10 compared to ZOL and PBO at approximately 4 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  9. Change from time-matched baseline on summary variables from quality of memory for LEM5 and LEM10 compared to ZOL and PBO at approximately 8 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  10. Change from time-matched baseline on summary variables from speed of memory retrieval for LEM5 and LEM10 compared to ZOL and PBO at approximately 4 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  11. Change from time-matched baseline on summary variables from speed of memory retrieval for LEM5 and LEM10 compared to ZOL and PBO at approximately 8 hours postdose [ Time Frame: approximately 4 hours postdose at each of 4 single-dose treatment periods (up to 43 days) ]
  12. Number of participants with any serious adverse event and number of participants with any non-serious adverse event [ Time Frame: up to 72 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, non-smoking female participants, aged 55 years and older, or male participants, aged 65 years and older, at the time of informed consent
  • Regular sleep timing and duration, per the following criteria:

    1. Regular time in bed, between 7 and 9 hours as reported at Screening and verified by the Sleep Diary during the Screening Period before the adaptation night such that time in bed is not less than 7 hours or more than 9 hours on more than 2 of the 7 consecutive nights recorded in the Sleep Diary
    2. Regular bedtime, defined as the time the participant attempts to fall asleep, between 22:00 and 01:00 and regular waketime, defined as the time the participant gets out of bed for the day, between 05:00 and 09:00 as reported at Screening and verified by the Sleep Diary during the Screening Period before the adaptation night such that neither bedtime nor waketime is outside of the permitted time windows on more than 2 of the 7 consecutive nights
  • Able to detect a 1000 Hertz (Hz) tone at 20 decibels (dB)
  • Able to read English at an 8th-grade level

Exclusion Criteria:

  • Is a female of childbearing potential Note: All females will be considered to be of childbearing potential unless they are postmenopausal (defined as amenorrheic for at least 12 consecutive months, and are postmenopausal without other known or suspected cause), or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
  • A current diagnosis of insomnia disorder, sleep-related breathing disorder, periodic limb movements disorder (PLMD), restless legs syndrome, circadian rhythm sleep disorder, narcolepsy, sleep-related violent behavior, sleep-driving, sleep-eating, or symptoms of another parasomnia that in the investigator's opinion make the participant unsuitable for the study
  • Has subjective sleep onset latency (sSOL) > 20 minutes or subjective wake after sleep onset (sWASO) > 60 minutes on more than 2 nights as reported on the Sleep Diary during the Screening Period before the adaptation night
  • Latency to persistent sleep (LPS) longer than 30 minutes as measured on the PSG on the Baseline night (or repeat Baseline night, if needed)
  • Has a sleep onset Rapid eye movemenet (REM) period, defined as first epoch of stage REM within 15 minutes of sleep onset, as measured on the PSG on either the adaptation night or Baseline night (or repeat Baseline night, if needed)
  • Apnea-Hypopnea Index > 15 or Periodic Limb Movement with Arousal Index > 15 as measured on the PSG on the adaptation night
  • Comorbid nocturia resulting in frequent need to get out of bed to use the bathroom during the night
  • History of fracture due to a fall within the past 5 years
  • Evidence of orthostatic hypotension at Screening
  • Use of hearing aid or clinically significant hearing loss
  • Presence or history of Meniere's disease, labyrinthitis, benign paroxysmal positional vertigo, no recent vertigo from any other cause, no recent dizziness or head injury
  • Unable to stand unaided for a minimum of 2 minutes
  • At Screening, fails Romberg test in the clinical judgment of the investigator
  • Significant vision loss or inability to read computer screen in <80 lumens per square meter (lux) ambient illumination
  • History of drug or alcohol dependency or abuse within approximately the previous 2 years or have a positive urine drug screen at Screening or Baseline
  • Self-reports consuming more than 14 alcohol-containing drinks per week (females) or 21 alcohol containing drinks per week (males) at Screening
  • A prolonged QT/heart rate corrected QT interval (QTc) (QT interval corrected for Fridericia's formula [QTcF] > 450 milliseconds [ms]) as demonstrated by a repeated electrocardiogram (ECG) at Screening (repeated only if initial ECG indicates a QTcF interval > 450 ms)
  • Any suicidal ideation at Screening or within 6 months of Screening or any lifetime suicidal behavior
  • Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal, psychiatric or neurological disease, malignancy other than basal cell carcinoma, or chronic pain) or condition that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
  • Used any prohibited prescription or over-the-counter concomitant medications within 1 week or 5 half lives, whichever is longer, before the Baseline night
  • Scheduled for surgery during the study
  • Transmeridian travel across more than 3 time zones in the 2 weeks before the first Baseline night, or plans to travel more than 3 time zones during the study.
  • Currently enrolled in another clinical trial or used any investigational drug or device within 28 days or 5 half lives, whichever is longer preceding informed consent
  • Hypersensitivity to lemborexant or zolpidem or any of their excipients
  • Active viral hepatitis (B or C) as demonstrated by positive serology
  • Previous exposure to lemborexant or suvorexant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03008447


Contacts
Contact: Eisai Medical Information 1-888-274-2378 esi_medinfo@eisai.com

Locations
United States, Georgia
NeuroTrials Research, Inc Recruiting
Atlanta, Georgia, United States, 30342
United States, New York
Clinilabs, Inc Recruiting
New York, New York, United States, 10019
United States, North Carolina
Wake Research Assoicates, LLC Recruiting
Raleigh, North Carolina, United States, 27612
United States, Ohio
Community Research Management Associates d/b/a CTI Clinical Research Center Recruiting
Cincinnati, Ohio, United States, 45212
Sponsors and Collaborators
Eisai Inc.
Purdue Pharma LP

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT03008447     History of Changes
Other Study ID Numbers: E2006-A001-108
First Posted: January 2, 2017    Key Record Dates
Last Update Posted: November 21, 2017
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: Yes

Keywords provided by Eisai Inc.:
E2006
postural stability
auditory awakening threshold
cognitive performance
healthy participants

Additional relevant MeSH terms:
Zolpidem
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action